ECSP105163A - Composiciones farmaceuticas de agonista parcial de 5ht4 - Google Patents

Composiciones farmaceuticas de agonista parcial de 5ht4

Info

Publication number
ECSP105163A
ECSP105163A EC2010005163A ECSP105163A ECSP105163A EC SP105163 A ECSP105163 A EC SP105163A EC 2010005163 A EC2010005163 A EC 2010005163A EC SP105163 A ECSP105163 A EC SP105163A EC SP105163 A ECSP105163 A EC SP105163A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
partial agonist
percent
weight
amount
Prior art date
Application number
EC2010005163A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP105163A publication Critical patent/ECSP105163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica sólida para administración oral, la cual comprende tegaserod en forma de base o de sal, en una cantidad de hasta el 10 por ciento en peso, un agente de volumen en una cantidad del 70 al 90 por ciento en peso, un desintegrante en una cantidad menor al 15 por ciento en peso, un abrillantador, y un lubricante.
EC2010005163A 2001-12-21 2010-06-16 Composiciones farmaceuticas de agonista parcial de 5ht4 ECSP105163A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
ECSP105163A true ECSP105163A (es) 2010-07-30

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010005163A ECSP105163A (es) 2001-12-21 2010-06-16 Composiciones farmaceuticas de agonista parcial de 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (es)
EP (2) EP1321142A1 (es)
JP (1) JP4718776B2 (es)
KR (1) KR100980144B1 (es)
CN (1) CN100464749C (es)
AR (1) AR037937A1 (es)
AT (1) ATE320807T1 (es)
AU (1) AU2002361198B2 (es)
BR (1) BR0215148A (es)
CA (1) CA2470668C (es)
CO (1) CO5640102A2 (es)
CY (1) CY1105559T1 (es)
DE (1) DE60210139T2 (es)
DK (1) DK1458377T3 (es)
EC (1) ECSP105163A (es)
EG (1) EG24194A (es)
ES (1) ES2258171T3 (es)
HU (1) HU226589B1 (es)
IL (2) IL162451A0 (es)
MX (1) MXPA04006157A (es)
MY (1) MY139546A (es)
NO (1) NO20042779L (es)
NZ (1) NZ533585A (es)
PE (1) PE20030872A1 (es)
PL (1) PL369509A1 (es)
PT (1) PT1458377E (es)
RU (1) RU2322978C2 (es)
SI (1) SI1458377T1 (es)
TW (1) TWI260221B (es)
WO (1) WO2003053432A1 (es)
ZA (1) ZA200404467B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
PT3395338T (pt) 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
PT1200090E (pt) * 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.

Also Published As

Publication number Publication date
SI1458377T1 (sl) 2006-08-31
MXPA04006157A (es) 2004-10-27
ATE320807T1 (de) 2006-04-15
MY139546A (en) 2009-10-30
CA2470668A1 (en) 2003-07-03
RU2004122631A (ru) 2005-08-10
IL162451A (en) 2009-02-11
US20090104263A1 (en) 2009-04-23
CO5640102A2 (es) 2006-05-31
EP1321142A1 (en) 2003-06-25
RU2322978C2 (ru) 2008-04-27
HU226589B1 (en) 2009-04-28
TWI260221B (en) 2006-08-21
CN100464749C (zh) 2009-03-04
CY1105559T1 (el) 2010-07-28
NO20042779L (no) 2004-09-17
ES2258171T3 (es) 2006-08-16
CN1606438A (zh) 2005-04-13
PE20030872A1 (es) 2003-11-24
AU2002361198B2 (en) 2006-06-08
DE60210139D1 (de) 2006-05-11
TW200410684A (en) 2004-07-01
KR20040066922A (ko) 2004-07-27
DE60210139T2 (de) 2006-08-17
EG24194A (en) 2008-10-14
AR037937A1 (es) 2004-12-22
CA2470668C (en) 2011-07-05
HUP0402492A3 (en) 2008-04-28
BR0215148A (pt) 2004-10-19
EP1458377A1 (en) 2004-09-22
WO2003053432A1 (en) 2003-07-03
AU2002361198A1 (en) 2003-07-09
ZA200404467B (en) 2006-05-31
HUP0402492A2 (hu) 2005-07-28
DK1458377T3 (da) 2006-06-12
IL162451A0 (en) 2005-11-20
PL369509A1 (en) 2005-04-18
US20050106236A1 (en) 2005-05-19
JP4718776B2 (ja) 2011-07-06
PT1458377E (pt) 2006-07-31
NZ533585A (en) 2006-04-28
KR100980144B1 (ko) 2010-09-03
EP1458377B1 (en) 2006-03-22
JP2005516946A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
ECSP105163A (es) Composiciones farmaceuticas de agonista parcial de 5ht4
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
CO5390076A1 (es) Composiciones farmaceuticas
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
TW200517106A (en) Sustained release pharmaceutical compositions
CO5590918A2 (es) Formulaciones
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
ECSP077262A (es) Composicion antihistaminica
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
BRPI0413676A (pt) composto, e, composição farmacêutica
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
AR070593A1 (es) Composiciones efervescentes
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
DK1768748T4 (da) Sammensætninger omfattende strontium og vitamin D og anvendelser deraf
MX2010004194A (es) Composicion oral que comprende un agente refrescante.
BR0318646A (pt) composição de branqueamento de dentes oral sólida
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
CY1113164T1 (el) Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη
ECSP045163A (es) Composiciones farmaceuticas de agonista parcial de 5ht4
ES2197781B1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
BRPI0407596A (pt) formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico
ES2165734T3 (es) Composiciones basadas en pentoxifilina y anticitoquina.